Maarten Frijlink active positions
| Companies | Position | Start | End |
|---|---|---|---|
Xenikos BV
 Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands. | Chief Operating Officer | 31/12/2014 | - |
Career history of Maarten Frijlink
Former positions of Maarten Frijlink
| Companies | Position | Start | End |
|---|---|---|---|
Kiadis Pharma BV
 Kiadis Pharma BV Pharmaceuticals: MajorHealth Technology Kiadis Pharma BV operates as a is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Its products include: ATIR101 and ATIR201. The firm’s products are based on hematopoietic blood-forming stem cell transplants from donors. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands. | Corporate Officer/Principal | - | - |
Statistics
International
| Netherlands | 3 |
Operational
| Corporate Officer/Principal | 1 |
| Chief Operating Officer | 1 |
Sectoral
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Kiadis Pharma BV
Kiadis Pharma BV Pharmaceuticals: MajorHealth Technology Kiadis Pharma BV operates as a is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Its products include: ATIR101 and ATIR201. The firm’s products are based on hematopoietic blood-forming stem cell transplants from donors. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
Xenikos BV
Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands. | Health Technology |
- Stock Market
- Insiders
- Maarten Frijlink
- Experience
